COGT as reported
Cogent Biosciences, Inc. reported $7.9M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.
$7.9M
Revenue, trailing twelve months · to Q4 2020 · every figure below is as filed, with no scoring applied
- Net Income
- −$377M
Net Income · +33% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$309M
Free Cash Flow · +32% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.16
EPS · +4.3% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $7.9M | n/a | Q4 2020 · 22 quarters behind |
| Net Income | −$377M | +33% | Q2 2026 |
| EPS | −$2.16 | +4.3% | Q2 2026 |
| Op Margin | −4952% | n/a | Q3 2020 · 23 quarters behind |
| Net Margin | −4373% | n/a | Q3 2020 · 23 quarters behind |
| ROE | −70% | n/a | Q2 2026 |
| ROA | −47% | n/a | Q2 2026 |
| ROIC | 708% | n/a | Q2 2026 |
| Free Cash Flow | −$309M | +32% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Cogent Biosciences, Inc. (COGT) - Revenue & ProfitRevenue & ProfitCogent Biosciences, Inc. (COGT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com